|
 |
|
NEWS RELEASE:
FOR IMMEDIATE RELEASE:
|
|
|
CEDARA SOFTWARE ANNOUNCES AGREEMENT WITH BIOTRONICS 3D ON
NEW C4 CLINICAL PLUG-IN MODULES
Contract to widen Cedara’s range of C4™ enabled applications available for clinical use
Toronto, ON, May 30, 2007 – Cedara Software, a Merge Healthcare company (NASDAQ: MRGE; TSX: MRG) and a leading independent developer of medical software technologies for the global healthcare market, announced an agreement with Biotronics3D, Ltd., that grants the London-based software company a license to market C4 enabled versions of its 3Dnet Suite™ family of 3D visualization software*. Under the agreement, Biotronics3D will distribute C4 enabled Biotronics3D applications to the growing number of OEMs that are adopting the C4 framework and other C4 clinical application modules from Cedara and its other partners.
The C4 ( Cedara Clinical Control Center) platform is a software framework that enables a host application to obtain plug-and-play access to a diverse array of clinical application modules after completing a one-time integration. C4 enabled plug-in modules can be launched from any C4 enabled host, a PACS or clinical workstation for example. The growing portfolio of C4 enabled plug-in modules now includes three Biotronics3D applications (3D Virtual Colonoscopy, 3D General Diagnostic and 3D angiography*) and Cedara’s own C4 enabled applications, including I-ReadMammo™** (mammography), PET/CT** and OrthoWorks Pro Planner™ (orthopaedics).
"I believe the addition of the 3Dnet Suite to the growing portfolio of Cedara C4 enabled applications gives OEM suppliers of PACS workstations a convenient way to offer to healthcare providers many clinical applications that are in high demand," said Haralambos Hatzakis, CEO of Biotronics3D. "The synergies between Cedara and Biotronics3D solutions based on the C4 integration platform will help clinicians improve workflow and could help contribute to diagnostic accuracy in CT, MRI and PET studies.
"We selected Biotronics3D to be a key partner based on the obvious synergies that our solutions possess together," said Loris Sartor, president of Cedara Software. "With this agreement, Cedara significantly strengthens its portfolio of clinical solutions that we can offer customers that use C4 enabled products."
C4 enabled 3D Virtual Colonoscopy, 3D Angiography and 3D General Diagnostic modules
The Biotronics3D 3Dnet™ product suite is a protocol-driven set of tools that permits clinicians to intuitively visualize the patient’s MRI, CT and PET studies in 3D on a standard Windows-based PC. 3Dnet™ can be integrated with a hospital’s or imaging center’s PACS or RIS/PACS to provide a seamless experience for clinicians. In addition, because 3Dnet™ applications do not require any proprietary or specialized hardware to operate, they may be deployed throughout the healthcare enterprise at relatively low cost.
Virtual colonoscopy: Fully integrated into the C4 framework, 3Dnet™ Suite Virtual Colonoscopy will enable clinicians to perform non-invasive virtual colonoscopy from CT colonography exams, affording patients a more comfortable alternative to traditional scope colonoscopy.
General Diagnostic: Fully integrated into the C4 framework, 3Dnet™ Suite, General Diagnostic will provide physicians with complete 3D visualization of multi-modality datasets.
Angiography: Fully integrated into the C4 framework, 3Dnet™ Suite Angiography will enable cardiologists to load CT angiography exams and visualize vessel structures for at-a-glance identification of structural anomalies that may correspond to aneurysm, calcifications, and stenoses.
About C4
C4 ( Cedara Clinical Control Center) is an integration framework that enables clinical application integration with minimal impact on the host (e.g. PACS) software product. A C4 enabled host and clinical application provide an integrated desktop with procedure-centric workflow.
*Note: C4 enabled versions of Biotronics3D 3Dnet™ Suite software products are works-in-progress. Cedara assumes no responsibility for the accuracy of any information provided directly to customers relating to Biotronics3D and/or 3Dnet Suite.
**Note: C4 enabled I-ReadMammo™ and C4 enabled PET/CT are works-in-progress.
# # #
Biotronics3D, headquartered in London, England, develops and markets innovative software applications for the diagnostic imaging industry. With an objective of transforming the way that healthcare providers interact with 3D images, Biotronics3D provides cutting edge software technologies to improve healthcare by better extracting diagnostic data and transforming it into usable information available at the point-of-care. Additional information about Biotronics3D may be found at www.biotronics3d.com.
Cedara Software is a Merge Healthcare company focused on the development of customized software solutions and development tools for the medical imaging OEM market. Cedara’s solutions enable OEM companies to accelerate their time-to-market, reduce development costs and access new streams of revenue. Cedara’s software is deployed in hospitals and clinics worldwide and is licensed by many of the world's leading medical device and healthcare information technology companies. Cedara’s technologies and engineering services span all the major digital imaging modalities and a wide variety of clinical specialties including radiology, orthopaedics, women’s health, oncology, cardiac imaging, clinical trials, imaging for the veterinarian market and more. For additional information, visit our website at www.cedara.com .
Merge Healthcare is a leading medical imaging software and services company. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at www.mergehealthcare.com.
All trademarks appearing in this release are the property of Cedara Software Corp. and/or Merge Healthcare.
|
Attn: Beth Frost-Johnson
Merge Healthcare
6737 West Washington St.
Suite 2250
Milwaukee, WI 53214
|
|
 |
|
|
|
| Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.
|
|
|
